rs66800491 — PVRL3

PVRL3 and Motion Sickness — When Your Eyes and Balance Disagree

Motion sickness strikes roughly one in three people and is among the most common neurological complaints during travel. The core mechanism is the sensory conflict model¹¹ sensory conflict model
also called the neural mismatch theory: the brain receives discordant signals from the vestibular (balance), visual, and proprioceptive systems during passive motion. In a car or on a ship, the inner ear signals movement while the eyes — focused on a book or a screen — signal stillness. The brain interprets this mismatch as potential poisoning and triggers nausea as a protective reflex. The genetics of motion sickness susceptibility points, surprisingly, to the visual side of this equation.

rs66800491 is an intergenic variant located approximately 1.1 megabases upstream of PVRL3 (now called NECTIN3)²² PVRL3 (now called NECTIN3)
the nectin cell adhesion molecule 3; nectins are immunoglobulin-like proteins that mediate cell-cell adhesion at adherens junctions and are essential for organogenesis. In the 2015 23andMe motion sickness GWAS, rs66800491 was the strongest association out of 35 genome-wide significant loci — the variant with the most statistical evidence for influencing how prone a person is to motion sickness.

The Mechanism

NECTIN3 encodes a cell adhesion protein required for normal ocular development. Loss of PVRL3 expression in both humans and mice causes congenital ocular defects including lens abnormalities³³ congenital ocular defects including lens abnormalities
mutations in PVRL3 are associated with autosomal recessive congenital cataracts and other structural eye defects in humans. The GWAS authors proposed that the PVRL3 locus influences motion sickness susceptibility through the visual channel of the sensory conflict system: if visual processing or the structural integrity of the visual apparatus is subtly altered, the fidelity of visual motion signals sent to the brain changes, amplifying the mismatch with vestibular input and increasing susceptibility to nausea.

The rs66800491 variant itself is intergenic — it does not change an amino acid. It likely acts as a [regulatory variant | variants in non-coding regions can alter gene expression levels by affecting enhancers, promoters, or long-range chromatin contacts] that modulates PVRL3 expression in developing or mature neural or ocular tissue. The A allele (risk allele, frequency ~29% globally) is associated with increased motion sickness susceptibility, with each A allele adding approximately 0.08 points on the 0–3 motion sickness severity scale. The effect is 1.5× larger in women than in men.

The Evidence

The primary evidence is Hromatka et al. 2015⁴⁴ Hromatka et al. 2015
Genetic variants associated with motion sickness point to roles for inner ear development, neurological processes and glucose homeostasis. Human Molecular Genetics, the first genome-wide association study of motion sickness, surveying 80,494 individuals from the 23andMe database who reported car sickness on a four-point scale (never, occasionally, sometimes, frequently). rs66800491 reached P = 4.2×10⁻⁴⁴ — far beyond the genome-wide significance threshold of 5×10⁻⁸ — making it the single strongest genetic signal for motion sickness susceptibility identified to date. The 35 identified loci together explain approximately 2.9% of the variance in motion sickness susceptibility. The PVRL3 locus was explicitly named among the top candidate genes because of its known role in eye and ear development.

The overall architecture of motion sickness genetics confirmed the sensory conflict model: the genome-wide significant loci cluster near genes for inner ear development (TSHZ1, MUTED), eye development (PVRL3), and craniofacial morphogenesis (HOXB3, HOXD3). This convergent signal across visual and vestibular development genes is biologically coherent — it is not a single pathway but rather the two endpoints of the sensory conflict axis.

Practical Actions

Motion sickness management is well-studied clinically and applies with particular force to people carrying the A allele at rs66800491. The most actionable interventions target the visual channel directly — which is the proposed biological pathway for this locus — or use pharmacological agents that dampen the brain's response to sensory conflict.

Behavioral strategies: fixing gaze on the true horizon (not a nearby fixed point inside the vehicle) provides the visual system with a stable motion reference that matches vestibular input, reducing the mismatch signal. Closing the eyes or lying down removes visual input entirely. Avoiding reading and screens during motion is particularly relevant given the PVRL3 visual mechanism — screens provide high-contrast stationary visual input that maximally conflicts with inner-ear motion signals.

Pharmacological: [transdermal scopolamine | a muscarinic acetylcholine receptor antagonist; brand name Transderm Scop; applied as a patch behind the ear] should be applied several hours before anticipated travel for full effect — it prevents nausea but is not effective once symptoms have started. First-generation antihistamines (dimenhydrinate, cinnarizine) are effective prevention alternatives but cause sedation.

Interactions

The motion sickness GWAS identified 35 loci, suggesting polygenic susceptibility. The PVRL3 locus is the strongest single signal but does not account for the full genetic architecture. The strongest comorbidities are with migraine, postoperative nausea/vomiting, vertigo, and morning sickness — all conditions involving the vestibular-visual-nausea axis. Individuals with genetic susceptibility to migraine (e.g., TRPM8 or PRDM16 variants) may have compounded motion sickness risk.